PD-1
-
开卷！全球首款皮下注射 PD-1 获FDA批准上市
延续十年之久的KO大战，出现了些许变数。 2024年12月28日，FDA批准了BMS的Opdivo皮下注射剂Opdivo Qvantig（nivolumab加透明质酸酶）上市，用于…
-
In the midst of a market downturn, with a year-on-year sales increase of 50%, what did this biopharma do right?
A Biopharma with outstanding product innovation and internal adjustment capabilities has no reason not to navigate through the cycle
-
As the 10th anniversary of approval approaches，Keytruda adds ‘potential’ performance to Merck
DrugTimes will follow up on this subject. Please stay tuned
-
Is it too early for Akeso and Summit to celebrate? Merck executive comments on the explosive news that Keytruda has been successfully challenged
Just our two cents. All comments, including criticisms, are warmly welcome. Thank you all very much!
-
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC
Monotherapy Ivonescimab Achieved Clinically Meaningful PFS Benefit in HARMONi-2 Tri…
-
最新汇总！2020获批的PD-1/L1疗法，囊括13类癌症
本文转自：环宇达康，药时代授权转载，衷心感谢！点击阅读原文 免疫疗法是攻克癌症的希望，通过激活人体自身的免疫系统攻击癌症的方式已被证实可以用于所有的实体肿瘤，这种旨在充分利用人体自…
-
HLA-I分子加工和递呈抗原功能受损是免疫检查点抑制剂耐药的重要原因
药时代，我们帮您找到理想的合作伙伴！ 摘要 目前，我们对获得性免疫检查点抑制剂(ICI)耐药的机制知之甚少。有文献报道，黑色…
-
PD-1/PD-L1阻断剂治疗肿瘤的研究进展与面临的挑战
药时代诚聘英才！ 本文转自：OncoLab实验室 众所周知，免疫检查点抑制剂（ICI）能够增强效应T细胞功能，使许多患者病情得到缓解。在过去的十几年中，ICI 彻底改变了晚期恶性肿…
-
来了！第4代CAR-T细胞疗法上场！CAR-T细胞表达PD-1，实体瘤治疗效果大大增加
本文授权转载自：上海细胞治疗工程技术研究中心 CAR-T免疫细胞疗法，全称是Chimeric Antigen Receptor T-Cell Immunotherap…
-
PD-1将成新药投资滑铁卢！还有靶点正重蹈PD-1覆辙，涉15家企业
精彩亮点： PD-1是创新吗？再过五年，不是给大家打针，是用PD-(L)1给大家洗澡。 CLDN18.2靶点正重蹈PD-1单抗覆辙，全球15家，美国只有2家，中国最多。 投生物制药…
